Hilden, Germany, and Germantown, Maryland, October 17, 2018 – QIAGEN today announced the winners of its fifth annual 2018 Microbiome Awards, a competition for outstanding researchers working on diverse aspects of the microbiome. The prize package totals more than $100,000. This year’s winner in the Ph.D. Scientist category is Dr. Hannah Wardill of The University... Read more
Hilden, Germany, and Germantown, Maryland, October 15, 2018– QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the European rollout of its next-generation QIAstat-Dx panel for one-step, fully integrated molecular analysis of gastrointestinal (GI) syndromes. The multiplex gastrointestinal panel, which QIAGEN has upgraded to now include comprehensive viral coverage detects the 24 most common viral,... Read more
Hilden, Germany, and Germantown, Maryland, Oct. 11, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of a breakthrough technology enabling faster, simpler library preparation for RNA sequencing. A key element of this portfolio is the QIAseq FastSelect RNA Removal Kit which provides a novel solution for scientists to target... Read more
Approval allows use of therascreen® EGFR RGQ PCR Kit as a companion diagnostic for Pfizer’s VIZIMPRO® (dacomitinib) in patients with non-small cell lung cancer Germantown, Maryland, and Hilden, Germany, September 28, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has approved a PMA Supplement... Read more
Hilden, Germany, and Germantown, Maryland, September 28, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today applauded a commitment by world leaders attending the first-ever high-level United Nations meeting on tuberculosis (TB) to mobilize $13 billion a year by 2022 to implement prevention and care for TB, the world’s most deadly infectious disease.... Read more
Hilden, Germany, and Saluggia, Italy, September 17, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and DiaSorin (FTSE Italy Mid Cap: DIA) today announced the introduction of an automated, CE-marked workflow for QIAGEN’s QuantiFERON-TB Gold Plus Blood Collection Tubes (QFT-Plus BCT) and a novel DiaSorin LIAISON Test on widely used immunodiagnostic instruments from... Read more
Hilden, Germany, and Ann Arbor, Michigan, September 17, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and NeuMoDx Molecular, Inc. today announced a strategic partnership to commercialize two new fully integrated systems for automation of PCR (polymerase chain reaction) testing. These next-generation systems are specifically designed to help clinical molecular diagnostic laboratories process... Read more
Hilden, Germany, and Germantown, Maryland, September 12, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that its global shares will be included in Germany’s MDAX index as of September 24, 2018, in addition to the current listing in the country’s TecDAX index. The addition to the MDAX – which will now... Read more
SEP 04 2018 QIAGEN N.V. announces that it will initiate the repurchase of a second tranche of shares under the share repurchase program which was announced by an ad hoc announcement dated January 31, 2018. In the time period between September 5, 2018 until November 14, 2018, at the latest, a second tranche of up... Read more
Hilden, Germany, and Johannesburg, South Africa, August 20, 2018 – QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the appointment of The Scientific Group, a South Africa-based company and wholly owned subsidiary of Ascendis Medical, as its exclusive commercial partner for Africa, excluding South Africa and the Maghreb. The agreement will raise the profile... Read more